In vitro metabolism of montelukast by cytochrome P450S and UDP-glucuronosyltransferases

Drug Metabolism and Disposition

Volumn 43, Issue 12, 2015, Pages 1905-1916

  De Oliveira Cardoso, Josiane ^a,b   Oliveira, Regina Vincenzi ^b   Lu, Jessica Bo Li ^a   Desta, Zeruesenay ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A3; MONTELUKAST; ACETIC ACID DERIVATIVE; QUINOLINE DERIVATIVE;

AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOCHEMISTRY; SULFOXIDATION; CHEMISTRY; DOSE RESPONSE; METABOLISM; PROCEDURES; TANDEM MASS SPECTROMETRY;

ACETATES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONOSYLTRANSFERASE; HUMANS; MICROSOMES, LIVER; QUINOLINES; TANDEM MASS SPECTROMETRY;

EID: 84948957404     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.065763     Document Type: Article

References (32)

1. Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, and Neuvonen PJ (2009) CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos 37:2359-2366.
2. Balani SK, Xu X, Pratha V, Koss MA, Amin RD, Dufresne C, Miller RR, Arison BH, Doss GA, and Chiba M, et al. (1997) Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos 25:1282-1287.
3. Bharathi DV, Hotha KK, Jagadeesh B, Mullangi R, and Naidu A (2009) Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. Biomed Chromatogr 23:804-810.
4. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, and Somers G (1996) Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 13:445-448.
5. Chiba M, Xu X, Nishime JA, Balani SK, and Lin JH (1997) Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 25: 1022-1031.
6. Dahlén SE, Hedqvist P, Hammarström S, and Samuelsson B (1980) Leukotrienes are potent constrictors of human bronchi. Nature 288:484-486.
7. De Lepeleire I, Reiss TF, Rochette F, Botto A, Zhang J, Kundu S, and Decramer M (1997) Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 61:83-92.
8. Faed EM (1984) Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 15:1213-1249.
9. Filppula AM, Laitila J, Neuvonen PJ, and Backman JT (2011) Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos 39:904-911.
10. Gan J, Chen W, Shen H, Gao L, Hong Y, Tian Y, Li W, Zhang Y, Tang Y, and Zhang H, et al. (2010) Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol 70:870-880.
11. Hegazy SK, Mabrouk MM, Elsisi AE, and Mansour NO (2012) Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers. Eur J Clin Pharmacol 68:1275-1280.
12. Jinno N, Tagashira M, Tsurui K, and Yamada S (2014) Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes. Xenobiotica 44:677-686.
13. Jones TR, Metters K, and Evans AJ (2001) Preclinical pharmacological studies with montelukast (Singulair), a selective cysteinyl leukotriene receptor(CysLT1) antagonist. Clinical and Experimental Allergy Reviews 1:205-209.
14. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, and Backman JT (2010) Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 88:223-230.
15. Karonen T, Neuvonen PJ, and Backman JT (2012) CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol 73:257-267.
16. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, and Becker A; Pediatric Montelukast Study Group (1998) Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 279:1181-1186.
17. Lewis RA, Austen KF, and Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323:645-655.
18. Mougey EB, Feng H, Castro M, Irvin CG, and Lima JJ (2009) Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19:129-138.
19. Niemi M, Neuvonen PJ, and Kivistö KT (2001) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 70:439-445.
20. Noé J, Portmann R, Brun M-E, and Funk C (2007) Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35: 1308-1314.
21. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
22. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, and Baillie TA (2002) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042-1051.
23. Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, Kundu S, and Zhang J (1996) Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 98:528-534.
24. Ritter JK (2007) Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 3:93-107.
25. Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, and Kurihara A, et al. (2010) Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos 38:1857-1864.
26. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227-17237.
27. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
28. Trontelj J (2012) Quantification of glucuronide metabolites in biological matrices by LC-MS/MS, in: Tandem Mass Spectrometry-Applications and Principles (Prasain JK ed), InTech ISBN 978-953-51-0141-3, available at: http://www.intechopen.com/books/tandem-mass-spectrometryapplications-and-principles/quantification-of-glucuronide-metabolites-in-biological-matricesby-lc-ms-ms.
29. VandenBrink BM, Foti RS, Rock DA, Wienkers LC, and Wahlstrom JL (2011) Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 39:1546-1554.
30. Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, Ryder TF, Obach RS, Hyland R, and Goosen TC (2012) Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos 40:1051-1065.
31. Walsky RL, Obach RS, Gaman EA, Gleeson JPR, and Proctor WR (2005) Selective inhibition of human cytochrome P450 2C8 by montelukast. Drug Metab Dispos 33:413-418.
32. Wen X, Wang JS, Backman JT, Kivistö KT, and Neuvonen PJ (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359-1361.